Omnipharm Research International Inc.

Buffalo, NY 14207

SBIR Award Summary

Total Number of Awards 10
Total Value of Awards $1.05MM
First Award Date 09/30/92
Most Recent Award Date 09/15/02

Key Personnel

Last Name Name Awards Contact
Walters Kenneth Walters 1
Coburn Robert A Coburn 3
Dunn Joseph A Dunn 6

10 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/02 - 02/28/03

DESCRIPTION (provided by applicant): The goal of this revised Phase 1 proposal remains to identify and initiate the pharmaceutical development of a topical formulation ingredient capable of reducing the risk associated with dermal and systemic exposure to hazardous materials (i.e., a permeation retarder). The strategy is to select a lead chemica...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/09/02 - 02/28/03

DESCRIPTION (provided by applicant): The goal of this program is to develop a topical pharmaceutical formulation containing an optimized drug candidate from the 5-(n-substituted)salicylanilide class of patented, Lipophilic, Antimicrobial, Anti-inflammatory Drugs (LAADs) for the treatment of Diabetic Foot Ulcer (DFU). The 5-(n-substituted)salicyl...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/01 - 08/31/02

DESCRIPTION (Adapted from the application): This Phase II grant application is to develop Trifluorosal (TMF-12), a derivative of lipophilic, 5-(n-alkylsulfonyl) salicylanilides. Since this agent is proposed to have anti-inflammatory properties and antimicrobial activity, including activity against P. acnes, ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/00 - 08/31/01

DESCRIPTION (Adapted from the application): This Phase II grant application is to develop Trifluorosal (TMF-12), a derivative of lipophilic, 5-(n-alkylsulfonyl) salicylanilides. Since this agent is proposed to have anti-inflammatory properties and antimicrobial activity, including activity against P. acnes, ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/03/00 - 07/31/01

The objective of this proposal is to determine if Trifluorosal, a new proprietary anti-inflammatory drug possessing other beneficial properties, can prevent the formation of UV induced papillomas and carcinomas in exposed mouse skin when applied topically. Trifluorosal belongs to a class of patented antibacterial/anti-inflammatory agents, the 5...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/99 - 03/31/01

Periodontal infections, which affect a large portion of the population, are responsible for the loss of teeth in adults and likely contribute to systemic disease. The most common method of controlling periodontal infections is my daily mechanical plaque removal. However, many individuals, due to lac...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/98 - 03/31/99

Periodontal infections, which affect a large portion of the population, are responsible for the loss of teeth in adults and likely contribute to systemic disease. The most common method of controlling periodontal infections is my daily mechanical plaque removal. However, many individuals, due to lac...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/97 - 09/29/98

The overall goal of this project is to develop and market a new topical treatment for acne that contains a 5-alkysulfonylsulfonylsalicylanilide as the active agent. The 5-alkylsulfonylsalicylanilides are a unique class of highly lipophilic compounds that possess both potent anti- inflammatory and antimi...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/95 - 03/29/97

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/92 - 03/31/94

The proposed research is intended to develop topical formulations of two new 2-2-dimethylphosphoraziridine antineoplastic agents and to evaluate these formulations in-vivo in a murine squamous cell carcinoma model system of human cancer. These two compounds were chosen because of their ability to inhibit the growth of human epidermal carcinoma ...

Load More